Metformin Intervention-A Panacea for Cancer Treatment?

Angelika Buczyńska1, Iwona Sidorkiewicz1, Adam Jacek Krętowski1,2

  • 1Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Cancers
|March 10, 2022
PubMed

Insights

Metformin offers numerous health benefits, including anti-cancer and anti-inflammatory effects. This review highlights its potential in cancer treatment and prevention, supported by promising clinical trial data.

Area of Science:

  • Pharmacology and Oncology
  • Metabolic Disease Research

Background:

  • Metformin's molecular mechanisms and metabolic pathway influences are under investigation.
  • Metformin exhibits pleiotropic effects, including anti-inflammatory, anti-cancer, and organ-protective properties.

Purpose of the Study:

  • To review novel evidence on metformin intervention, focusing on cancer treatment and prevention.
  • To summarize promising results from human trials of metformin.

Main Methods:

  • Literature review of existing data on metformin's effects.
  • Analysis of metformin's role in various cellular contexts.

Main Results:

  • Metformin demonstrates anti-inflammatory, anti-cancer, hepatoprotective, cardioprotective, otoprotective, radioprotective, and radio-sensitizing properties.
  • Key actions include inhibiting inflammation, boosting antioxidant capacity, and improving metabolic profiles.

Conclusions:

  • Metformin's diverse actions make it a promising candidate for cancer therapy and prevention.
  • Clinical trial data supports metformin's translation into human cancer treatment protocols.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
326
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
302